Whitehawk Therapeutics (WHWK) Cash & Equivalents (2010 - 2026)
Whitehawk Therapeutics (WHWK) reported Cash & Equivalents of $34.8 million for Q1 2026, down 84.71% year-over-year from $227.6 million in Q1 2025, and down 7.39% on a QoQ basis from $37.6 million in Q4 2025.
Whitehawk Therapeutics (WHWK) has 17 years of Cash & Equivalents data on file, last reported at $34.8 million in Q1 2026.
- Quarterly Cash & Equivalents fell 84.71% year-over-year to $34.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $34.8 million (down 84.71% YoY) and the FY2025 annual result came in at $37.6 million, up 31.04% from the prior year.
- Cash & Equivalents declined to $34.8 million in Q1 2026 per WHWK's latest filing, from $37.6 million in the prior quarter.
- Across five years, Cash & Equivalents topped out at $227.6 million in Q1 2025 and bottomed at $28.7 million in Q4 2024.
- The 5-year median for Cash & Equivalents is $62.9 million (2023), against an average of $83.4 million.
- The widest annual swing landed in 2025, when Cash & Equivalents jumped 432.47%; it then plunged 84.71% in 2026.
- Tracing WHWK's Cash & Equivalents over 5 years: stood at $39.0 million in 2022, then surged by 61.17% to $62.9 million in 2023, then plunged by 54.41% to $28.7 million in 2024, then surged by 31.04% to $37.6 million in 2025, then slipped by 7.39% to $34.8 million in 2026.
- Per Business Quant, the three latest WHWK Cash & Equivalents figures stand at $34.8 million (Q1 2026), $37.6 million (Q4 2025), and $162.6 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 1.91 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 32.30 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 286.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 61.46 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 2.77 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 5.49 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 18.44 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 2.96 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.71 Bn |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | 34.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.79 Mn |
| Dec 31, 2025 | 37.57 Mn |
| Sep 30, 2025 | 162.60 Mn |
| Jun 30, 2025 | 144.94 Mn |
| Mar 31, 2025 | 227.57 Mn |
| Dec 31, 2024 | 28.67 Mn |
| Sep 30, 2024 | 30.54 Mn |
| Jun 30, 2024 | 41.14 Mn |
| Mar 31, 2024 | 53.78 Mn |
| Dec 31, 2023 | 62.89 Mn |
| Sep 30, 2023 | 68.80 Mn |
| Jun 30, 2023 | 68.16 Mn |
| Mar 31, 2023 | 34.05 Mn |
| Dec 31, 2022 | 39.02 Mn |
| Sep 30, 2022 | 134.82 Mn |
| Jun 30, 2022 | 118.74 Mn |
| Mar 31, 2022 | 129.80 Mn |
| Dec 31, 2021 | 148.99 Mn |
| Sep 30, 2021 | 161.38 Mn |
| Jun 30, 2021 | 36.82 Mn |
| Mar 31, 2021 | 39.01 Mn |
| Dec 31, 2020 | 4.46 Mn |
| Sep 30, 2020 | 47.28 Mn |
| Jun 30, 2020 | 44.86 Mn |
| Mar 31, 2020 | 34.58 Mn |
| Dec 31, 2019 | 38.52 Mn |
| Sep 30, 2019 | 43.39 Mn |
| Jun 30, 2019 | 48.16 Mn |
| Mar 31, 2019 | 53.42 Mn |
| Dec 31, 2018 | 62.61 Mn |
| Sep 30, 2018 | 68.81 Mn |
| Jun 30, 2018 | 68.78 Mn |
| Mar 31, 2018 | 13.76 Mn |
| Dec 31, 2017 | 20.26 Mn |
| Sep 30, 2017 | 24.83 Mn |
| Jun 30, 2017 | 28.85 Mn |
| Mar 31, 2017 | 35.14 Mn |
| Dec 31, 2016 | 1.61 Mn |
| Sep 30, 2016 | 1.31 Mn |
| Jun 30, 2016 | 1.60 Mn |
| Mar 31, 2016 | 1.16 Mn |
| Dec 31, 2015 | 5.14 Mn |
| Sep 30, 2015 | 6,270.00 |
| Jun 30, 2015 | 10,095.00 |
| Mar 31, 2015 | 23,287.00 |
| Dec 31, 2014 | 5,263.00 |
| Sep 30, 2014 | 17,868.00 |
| Jun 30, 2014 | 4,568.00 |
| Mar 31, 2014 | 5,883.00 |
| Dec 31, 2013 | 6,283.00 |
| Sep 30, 2013 | 10,295.00 |
| Jun 30, 2013 | 2,706.00 |
| Mar 31, 2013 | 2,706.00 |
| Dec 31, 2012 | 4,607.00 |
| Sep 30, 2012 | 5,391.00 |
| Jun 30, 2012 | 9,311.00 |
| Mar 31, 2012 | 23,598.00 |
| Dec 31, 2011 | 4,125.00 |
| Sep 30, 2011 | 6,130.00 |
| Jun 30, 2011 | 9,230.00 |
| Mar 31, 2011 | 24,634.00 |
| Dec 31, 2010 | 26,898.00 |
| Sep 30, 2010 | 2,254.00 |